Pedal | Jotup

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Tuesday, February 27, 2024

ET –

Key Points:

ET –
SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2023 financial results and provided a corporate update.
Research and development (R&D) expenses for the fourth quarter of 2023 were $32.5 million, compared to $22.7 million for the fourth quarter of 2022.
General and administrative (G&A) expenses for the fourth quarter of 2023 were $14.2 million, compared to $12.5 million for the fourth quarter of 2022.
ET / 1:30 p.m. PT today, February 27, 2024, to discuss the financial results for the fourth quarter and full year 2023 and to provide a corporate update.

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Retrieved on:

Friday, December 8, 2023

Princess, Leukemia & Lymphoma Society, Partnership, Research, Bone marrow, KURA, Drug, Kura, SAN, Pedal, Clinical trial, Cancer, LLS, Leukemia, Patient, Acute leukemia, Pharmaceutical industry

“We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.

Key Points:

“We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.
“Kura remains committed to developing new treatment options across the continuum of care, including for pediatric patients with acute leukemias where poor outcomes and significant unmet medical need remain.
PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer.
Kura will supply LLS and the Princess Máxima Center with ziftomenib for the study.

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Retrieved on:

Sunday, December 10, 2023

“These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.

Key Points:

“These findings underscore the broad potential of uproleselan, if successfully developed in combination with existing therapies, to benefit people with heterogeneous forms of AML.
Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
This Phase 1b/2 clinical trial evaluated safety, tolerability, and preliminary efficacy of uproleselan added to cladribine and LDAC in patients with ts-AML.
This rare, high-risk study population is defined by prior chemotherapy treatment of a previous hematologic disorder, such as myelodysplastic syndrome.
Study investigators concluded these data support this low-risk approach to marrow blast reduction and disease control in preparation for HCT.

Global Cycling Power Meters Business Report 2024 - Growing Popularity of E-Bikes to Spur the Demand for Cycling Power Meters

Retrieved on:

Wednesday, December 13, 2023

Metre, Growth, COVID-19, Cycling power meter, Pedal

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- The "Cycling Power Meters - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- The "Cycling Power Meters - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Cycling Power Meters estimated at US$391.5 Million in the year 2022, is projected to reach a revised size of US$549.5 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2022-2030.
Shifting its focus, the report explores the effects of COVID-19 on the cycling power meters market and the key competitors' market share in 2023, along with their competitive market presence.
It provides insights into cycling power meters, their types, selection criteria, and global market trends, emphasizing rapid growth, particularly in the sports bicycle sector.

The Leukemia & Lymphoma Society (LLS) Data and Presence at ASH Showcase Latest Blood Cancer Treatment Breakthroughs

Retrieved on:

Tuesday, December 5, 2023

RYE BROOK, N.Y., Dec. 5, 2023 /PRNewswire/ -- At the 65th Annual American Society of Hematology (ASH) Annual Meeting (December 9-12 in San Diego), The Leukemia & Lymphoma Society (LLS) will present new research findings, and proudly support more than 200 LLS-funded researchers, as well as 15 current and former LLS Therapy Acceleration Program® (TAP) partners, who will share their study results.

Key Points:

The next big advances are in the works," said Lee Greenberger, Ph.D., LLS Chief Scientific Officer.
LLS funding has helped advance more than 70% of blood cancer treatment options approved by the U.S. Food and Drug Administration in the last six years.
LLS research selected for presentation at ASH includes:
New data from two master clinical trials convened and led by LLS: the Pediatric Acute Leukemia Master Clinical Trial ( PedAL ) and the Beat AML® Master Clinical Trial .
The Beat AML Master Clinical Trial, the first collaborative precision medicine clinical trial in blood cancer, uses advanced technology to provide genomic analysis to match patients to precision treatment within seven days.

Communities Across the U.S. to Join Olympians at Legendary Deer Valley Resort to End Blood Cancer

Retrieved on:

Monday, November 6, 2023

RYE BROOK, N.Y., Nov. 6, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is kicking off the ski season with huge goal in mind: to end blood cancer. Communities nationwide will be joined by past Olympians including Nordic skier Bryan Fletcher at LLS's "Shred For Red" event at the legendary Deer Valley Resort in Park City, UT, often referred to as "The Greatest Snow on Earth".

Key Points:

Communities nationwide will be joined by past Olympians including Nordic skier Bryan Fletcher at LLS's " Shred For Red " event at the legendary Deer Valley Resort in Park City, UT, often referred to as "The Greatest Snow on Earth".
Happening on December 2, Shred For Red is a fun and family-friendly event where dedicated volunteers raise funds to end blood cancer, while skiing some of the best slopes in the world and enjoying lively winter activities.
With a more than 70-year track record, LLS has supported virtually every advancement in blood cancer treatment.
Blood cancer patients and their families can contact the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

World's Most Successful Endurance Sports Training Program for Charity Honors Late Founder Bruce Cleland as 35th Year at TSC New York City Marathon Approaches

Retrieved on:

Thursday, November 2, 2023

RYE BROOK, N.Y., Nov. 2, 2023 /PRNewswire/ -- Each year, runners from more than 140 countries convene in New York City to participate in the largest marathon in the world. But for some, the experience is about more than just partaking in the race. Since 1988, more than 4,300 runners at the TSC New York City Marathon have raised funds for blood cancer patients, their families, and caregivers through The Leukemia & Lymphoma Society's (LLS) Team In Training program. And, in its 35th year at the world-renowned event, the impactful fundraising program shows no sign of slowing down as they reflect on how it all started — one dedicated father's determination to dream big.

Key Points:

Since 1988, more than 4,300 runners at the TSC New York City Marathon have raised funds for blood cancer patients, their families, and caregivers through The Leukemia & Lymphoma Society's (LLS) Team In Training program.
Team In Training was started in 1988 by Bruce Cleland in honor of his then two-year-old daughter, Georgia, who was diagnosed with acute lymphoblastic leukemia (ALL).
He gathered a team of 38 runners to train for and participate in the1988 New York City Marathon.
Join Team In Training to take on best-in-class endurance challenges worldwide – while raising money to pioneer groundbreaking research and advancements in the fight against cancer for LLS.

T-Mobile Revs Up 5G with Four-Carrier Aggregation

Retrieved on:

Tuesday, July 25, 2023

What’s the news: T-Mobile has begun rolling out four-carrier aggregation for customers, boosting speeds on its 5G standalone (SA) network.

Key Points:

What’s the news: T-Mobile has begun rolling out four-carrier aggregation for customers, boosting speeds on its 5G standalone (SA) network.
5G carrier aggregation allows T-Mobile to turbocharge 5G SA speeds, giving customers a game-changing performance boost.
“With the only nationwide 5G standalone network in the country, T-Mobile is the ONLY provider bringing game-changing technologies like four-carrier aggregation to customers across the country.”
5G carrier aggregation allows T-Mobile to combine multiple 5G channels (or carriers) to deliver greater speed and performance.
T-Mobile is the leader in 5G , delivering the country’s largest, fastest and most awarded 5G network .

Vässla Pedal e-Bike Now Available in New York City; Subscriptions Launching, Bringing the Best of Unisex Scandinavian Design to the Big Apple

Retrieved on:

Tuesday, April 11, 2023

Bicycle industry, Meizu PRO 6, City, Maintenance, United Rugby Championship, New Yorker, German Design Council, Club, Pedal, CO2, Mobile phone, Road, Flex

BROOKLYN and STOCKHOLM, April 11, 2023 /PRNewswire-PRWeb/ -- Today, Vässla announced the U.S. availability of its Vässla Pedal e-bike and the launch of Vässla Club, a subscription service for New Yorkers.

Key Points:

Today, Vässla announced the U.S. availability of its Vässla Pedal e-bike and the launch of Vässla Club, a subscription service for New Yorkers.
With integrated lights and gears, it incorporates the simplicity of Scandinavian design and has already earned a German Design Award following its launch in Europe in 2022.
BROOKLYN and STOCKHOLM, April 11, 2023 /PRNewswire-PRWeb/ -- Today, Vässla announced the U.S. availability of its Vässla Pedal e-bike and the launch of Vässla Club , a subscription service for New Yorkers.
The Pedal stands for the new urban era, and is an amazing product that I am very proud of."

TRANSMEDIA GROUP TO STEER MEDIA TO NEW, 'FAMILY-DRIVEN' PEDAL YARD™, BUNDLING CUSTOM LEARN-TO-RIDE TECHNIQUE WITH FIRST-OF-ITS-KIND POP-UP BIKE PARK & PLAY SPACES

Retrieved on:

Wednesday, March 22, 2023

Parenting, BOCA, Publication, Pedal, Safety, Research, Child, Mazzone, Road

BOCA RATON, Fla., March 22, 2023 /PRNewswire/ -- As the number of children who learn to ride a bike continues to decline, TransMedia Group's PR campaign will spotlight Pedal Yard™'s innovative, pro-active solutions that get 2-6 year olds riding and promote family bonding.

Key Points:

"The research is clear that our screen-driven society can quickly find better balance… on a bike," said TransMedia Group President, Adrienne Mazzone.
TransMedia Group will bring to reporters and editors Pedal Yard™ Founder Marc Abrams' energetic solutions, methodologies and program parameters.
"We are focused on giving parents/grandparents the tools and confidence to teach kids under 6- when fear factor is lowest- to ride a bike.
"And we're excited for TransMedia Group to spread the word reminding people to get off screens, get outside, get their kids on a bike… and that there's no easier spot than Pedal Yard™."